Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026, announced July 30, 2026.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026, announced July 30, 2026
- Full financial details contained in Exhibit 99.1 press release
- Disclosure furnished under Regulation FD and generally not subject to Section 18 filing liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 net revenue $74.3M, up 88% year over year and 27% sequentially, confirming accelerating VOQUEZNA commercialization
- Operating expenses fell 33% to $63.1M, driving near break-even adjusted net loss of $0.1M despite $6.7M stock compensation
- Approximately 1.7M VOQUEZNA prescriptions filled, with 325,000 in Q2 and 64% covered prescriptions supporting market access progress
- 2026 revenue guidance reduced to $310–325M from $320–345M, while non-GAAP expense guidance tightened to $235–245M
- Phase 3 as-needed VOQUEZNA trial expected to enroll in Q4 2026, creating potential NERD label expansion and additional market opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.